Who makes NNC0114-0000-0005?

NNC0114-0000-0005 is developed by Novo Nordisk A/S.

What development phase is NNC0114-0000-0005 in?

NNC0114-0000-0005 is in Phase 1.

Last reviewed 2026-05-14 · How we verify

NNC0114-0000-0005

Novo Nordisk A/S · Phase 1 active Small molecule

At a glance

Generic name	NNC0114-0000-0005
Sponsor	Novo Nordisk A/S
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NNC0114-0000-0005 CI brief — competitive landscape report
NNC0114-0000-0005 updates RSS · CI watch RSS
Novo Nordisk A/S portfolio CI